Table 1.

Features of selected managed access protocol case studies, as of November 2023

Managed access protocol reimbursement criteria	Liraglutide (Saxenda®) for weight management	Dupilumab (Dupixent®)b for atopic dermatitis	Calcitonin gene-related peptides* for chronic migraine
Limited prescribing authority		●	●
Clinical diagnostic criteria	●	●	●
Clinical severity criteria	●	●	●
Previous lines of treatment		●	●
Concomitant interventions	●	●
Outcome data collection as a condition of ongoing reimbursement support	●
Validations within reimbursement claims system	●	●	●

^aErenumab, fremanezumab, galcanezumab, and eptinezumab

^bAlso applies to other medicines for atopic dermatitis available on the high tech arrangement, specifically tralokinumab, abrocitinib and upadacitinib